Concepedia

Aisha Masood

AM

Statistics

Publications

22

Citations

1.8K

H-Index

16

Active since

2011

Affiliations

Novartis (Switzerland)(Current)

The University of Texas MD Anderson Cancer Center

Hôpital Saint-Louis

University of Pennsylvania

Roswell Park Comprehensive Cancer Center

Aisha Masood is an author at Novartis (Switzerland) specializing in medicine, immunology, and oncology.

Top concepts

Publications per year

2011–2024

22

Publications

22

Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial

Nathan Fowler, Michael Dickinson, Martin Dreyling et al. · Nature Medicine · 2021 · 492 citations · Full text

, , +6

Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma

Michael R. Bishop, Michael Dickinson, Duncan Purtill et al. · New England Journal of Medicine · 2021 · 491 citations · Full text

Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600–Mutant Unresectable or Metastatic Melanoma

Reinhard Dummer, Georgina V. Long, Caroline Robert et al. · Zurich Open Repository and Archive (University of Zurich) · 2022 · 146 citations · Full text

Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i

Reinhard Dummer, Célèste Lebbé, Victoria Atkinson et al. · Nature Medicine · 2020 · 121 citations

, , +9

Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update

Martin Dreyling, Nathan Fowler, Michael Dickinson et al. · Blood · 2024 · 81 citations · Full text

, , +23

Rows per page

1–5 of 22